New Mumbai corporate office inaugurated, described as the next phase of growth
Company inaugurated a new Mumbai corporate office, spread across 25,600 sq ft.
By ScoutQuest · · 2 min read
- New office area
- 25,600 sq ft
- New medicines and indications in India (past three years)
- More than 25
- Global clinical trials running in India
- About 80
New Mumbai corporate office inaugurated
- The company today inaugurated a new corporate office in Mumbai.
- The office is spread across 25,600 sq ft.
- It was inaugurated by Hon'ble Shri Devendra Fadnavis, Chief Minister of Maharashtra, alongside senior government officials, dignitaries from embassies and the AstraZeneca team.
What the release says about the India business
- More than 25 new medicines and indications have been introduced in India over the past three years.
- About 80 global clinical trials are currently being run in the country.
- The India workforce is described as nearly 5,000 colleagues across the country.
- Therapy areas mentioned: Oncology, Biopharmaceuticals and Rare Disease.
Management view
Praveen Rao Akkinepally, Country President and Managing Director, AstraZeneca Pharma India Limited, said India is at an important inflection point in healthcare, with a growing need for earlier diagnosis, innovative treatments and more equitable access, and that a stronger presence in Mumbai strengthens the company's ability to work with partners in the healthcare ecosystem.
Arun Krishna, Non-Executive Director on the Board of AstraZeneca Pharma India Limited and Area Vice President, Asia, AstraZeneca, said India is an increasingly important contributor to AstraZeneca's growth across Asia, and that the new commercial office in Mumbai will support closer engagement with stakeholders and continued development of people.
What the company says the office supports
- Closer and more effective partnership with the healthcare ecosystem across the therapy areas it is present in.
- Continued investment in talent and capability building in India.
- A broader footprint that supports commercial operations, site management and monitoring, technology, research and development, and global business services.
The release states that with this Mumbai office, AstraZeneca in India is entering its next phase of growth focused on expanding access to innovation, deepening partnerships and helping address the country's most pressing healthcare needs. The company also mentions focus on leveraging AI and building solutions across the continuum of care, from prevention, awareness, diagnosis and treatment, at scale.
How to read this
- This is an operational and corporate-presence update. It does not carry any financial results, order, contract or capital action.
- The figures here describe scale of activity in India, not revenue or profit.
- The perception it can create is of continued expansion of the company's India footprint and pipeline activity.
Also from AstraZeneca Pharma India
NSE Sustainability assigns ESG rating of 73 to AstraZeneca Pharma India for FY2025-26
16 Oct 2026
More numbers
- Area of the new Mumbai corporate office25,600 sq ft
- New medicines and indications introduced in India in the past three yearsmore than 25
- Global clinical trials running in Indiaabout 80
- India workforce mentioned in the releasenearly 5,000 colleagues
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.